{"protocolSection": {"identificationModule": {"nctId": "NCT01663233", "orgStudyIdInfo": {"id": "CLCZ696A2319"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine", "officialTitle": "A Randomized, 8-week, Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 5 mg Monotherapy Treatment"}, "statusModule": {"statusVerifiedDate": "2015-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-08"}, "primaryCompletionDateStruct": {"date": "2013-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-08-08", "studyFirstSubmitQcDate": "2012-08-10", "studyFirstPostDateStruct": {"date": "2012-08-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-07-21", "resultsFirstSubmitQcDate": "2015-07-21", "resultsFirstPostDateStruct": {"date": "2015-08-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-10-01", "lastUpdatePostDateStruct": {"date": "2015-10-23", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study will assess whether LCZ696 when used in combination with amlodipine will provide greater BP lowering benefit compared to amlodipine alone in Asian hypertensive patients not adequately responsive to amlodipine therapy."}, "conditionsModule": {"conditions": ["Essential Hypertension"], "keywords": ["Essential hypertension", "High blood pressure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 266, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LCZ696 and amlodipine", "type": "EXPERIMENTAL", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks.", "interventionNames": ["Drug: LCZ696", "Drug: Amlodipine"]}, {"label": "Amlodipine", "type": "ACTIVE_COMPARATOR", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks.", "interventionNames": ["Drug: Amlodipine", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "LCZ696", "description": "LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.", "armGroupLabels": ["LCZ696 and amlodipine"]}, {"type": "DRUG", "name": "Amlodipine", "description": "Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.", "armGroupLabels": ["Amlodipine", "LCZ696 and amlodipine"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo to LCZ696", "armGroupLabels": ["Amlodipine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (maSBP)", "description": "The change in mean 24 hour ambulatory systolic blood pressure (maSBP) from baseline to end of the study (week 8) in the 2 groups was measured. A greater reduction from baseline in the LCZ696 group indicates a positive treatment effect.", "timeFrame": "8 weeks"}], "secondaryOutcomes": [{"measure": "Change in Mean 24-hour ABPM Diastolic Blood Pressure (maDBP)", "description": "The change in mean 24 hour maDBP from baseline to end of the study was measured. A reduction from baseline indicates a positive treatment effect.", "timeFrame": "8 weeks"}, {"measure": "Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The change in the patient's msSBP from baseline to end of the study was measured. A reduction from baseline indicates a positive treatment effect.", "timeFrame": "8 weeks"}, {"measure": "Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The change in the patient's msDBP from baseline to end of the study was measured. A reduction from baseline indicates a positive treatment effect.", "timeFrame": "8 weeks"}, {"measure": "Change in Sitting Pulse Pressure (PP)", "description": "The change in the patient's mean sitting PP from baseline to end of the study was measured. Pulse pressure measures the difference in mean sitting systolic blood pressure and mean sitting diastolic blood pressure.", "timeFrame": "8 weeks"}, {"measure": "Number of Participants Achieving Systolic and Diastolic Blood Pressure Control (< 140/90 mmHg)", "description": "The number of participants achieving a systolic and diastolic blood pressure \\< 140/90 mmHg was measured. This outcome measure shows how well a given blood pressure treatment can achieve a given blood pressure target or goal. Participants who achieved the target blood pressure were determined based on the mean SBP and DBP measurements taken at the end of the study. If the participants' BP measurement was below the above target, they were considered to have successful blood pressure control.", "timeFrame": "8 weeks"}, {"measure": "Number of Participants Achieving Successful Response in msSBP (< 140 mmHg or a Reduction \u2265 20 mmHg From Baseline)", "description": "The number of participants who achieved successful treatment response in the msSBP of \\< 140mmHg or a reduction \u2265 20 mmHg from baseline after completing study treatment was measured. Participants who achieved either of the above targets were deemed as a having a successful response.", "timeFrame": "8 weeks"}, {"measure": "Number of Participants Achieving Successful Response in msDBP (< 90 mmHg or a Reduction \u2265 10 mmHg From Baseline)", "description": "The number of participants who achieved successful treatment response in msDBP of \\< 90mmHg or a reduction \u2265 10mmHg from baseline after completing study treatment was measured. Participants who achieved either of the above targets were deemed as having a successful response.", "timeFrame": "8 weeks of treatment"}, {"measure": "Number of Participants With Adverse Event", "description": "Participants were monitored for adverse events, serious adverse events and death.", "timeFrame": "8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nPatients must give written informed consent and have a diagnosis of hypertension:\n\nUntreated patients must have an msSBP \u2265 150 mmHg and \\< 180 mmHg at both Visit 1 and Visit 101. Pre-treated patients must have an msSBP \u2265 145 mmHg and \\< 180 mmHg after wash out at Visit 101. All patients must have an office msSBP \u2265 145 mmHg and \\< 180 mmHg at the completion of the 4-week run-in epoch (at the randomization visit (Visit 201).\n\nPatients must successfully complete ABPM and pass technical requirements at Visit 201.\n\nExclusion Criteria:\n\nMalignant or severe hypertension (grade 3 of WHO classification; msDBP \u2265110 mmHg and/or msSBP \u2265 180 mmHg).\n\nHistory of angioedema, drug-related or otherwise. History or evidence of a secondary form of hypertension. Transient ischemic cerebral attack (TIA) during the 12 months prior to Visit 1 or any history of stroke.\n\nHistory of myocardial infarction, coronary bypass surgery or PCI during the 12 months prior to Visit 1\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Shijiazhuang", "state": "Hebei", "zip": "050000", "country": "China", "geoPoint": {"lat": 38.04139, "lon": 114.47861}}, {"facility": "Novartis Investigative Site", "city": "Chongqing", "zip": "400042", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"facility": "Novartis Investigative Site", "city": "Shanghai", "zip": "200025", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Novartis Investigative Site", "city": "Tianjin", "zip": "300142", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"facility": "Novartis Investigative Site", "city": "Edogawa-ku", "state": "Tokyo", "zip": "133-0061", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Katsushika-ku", "state": "Tokyo", "zip": "124-0024", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Kiyose-city", "state": "Tokyo", "zip": "204-0021", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Kunitachi", "state": "Tokyo", "zip": "186-0001", "country": "Japan", "geoPoint": {"lat": 35.6833, "lon": 139.43848}}, {"facility": "Novartis Investigative Site", "city": "Shibuya-ku", "state": "Tokyo", "zip": "150-0002", "country": "Japan", "geoPoint": {"lat": 35.469, "lon": 140.29807}}, {"facility": "Novartis Investigative Site", "city": "Shinagawa-ku", "state": "Tokyo", "zip": "142-0063", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Novartis Investigative Site", "city": "Toshima-ku", "state": "Tokyo", "zip": "171-0021", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Wonju", "state": "Gangwon-Do", "zip": "220-701", "country": "Korea, Republic of", "geoPoint": {"lat": 37.35139, "lon": 127.94528}}, {"facility": "Novartis Investigative Site", "city": "Koyang", "state": "Kyunggi", "zip": "410-719", "country": "Korea, Republic of"}, {"facility": "Novartis Investigative Site", "city": "Busan", "zip": "602-739", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Novartis Investigative Site", "city": "Daegu", "zip": "705-703", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Novartis Investigative Site", "city": "Daegu", "zip": "705-718", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "zip": "150-713", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Kuching", "state": "Sarawak", "zip": "94300", "country": "Malaysia", "geoPoint": {"lat": 1.54999, "lon": 110.33333}}, {"facility": "Novartis Investigative Site", "city": "Kuala Lumpur", "zip": "56000", "country": "Malaysia", "geoPoint": {"lat": 3.1412, "lon": 101.68653}}, {"facility": "Novartis Investigative Site", "city": "Quezon City", "state": "Manila", "zip": "1100", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Novartis Investigative Site", "city": "Manila", "state": "Metro Manila", "zip": "1000", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Novartis Investigative Site", "city": "Quezon City", "zip": "1100", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Novartis Investigative Site", "city": "Quezon City", "zip": "1102", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Novartis Investigative Site", "city": "Valenzuela City", "zip": "1441", "country": "Philippines"}, {"facility": "Novartis Investigative Site", "city": "Taipei", "state": "Taiwan, ROC", "zip": "112", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Novartis Investigative Site", "city": "Taichung", "zip": "40447", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Novartis Investigative Site", "city": "Taipei", "zip": "10002", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Novartis Investigative Site", "city": "Taipei", "zip": "114", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks."}, {"id": "FG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "130"}, {"groupId": "FG001", "numSubjects": "136"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "126"}, {"groupId": "FG001", "numSubjects": "129"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks."}, {"id": "BG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "130"}, {"groupId": "BG001", "value": "136"}, {"groupId": "BG002", "value": "266"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.4", "spread": "9.31"}, {"groupId": "BG001", "value": "55.5", "spread": "9.43"}, {"groupId": "BG002", "value": "55.4", "spread": "9.35"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "110"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "75"}, {"groupId": "BG002", "value": "156"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (maSBP)", "description": "The change in mean 24 hour ambulatory systolic blood pressure (maSBP) from baseline to end of the study (week 8) in the 2 groups was measured. A greater reduction from baseline in the LCZ696 group indicates a positive treatment effect.", "populationDescription": "FAS: This set included all randomized participants who received at least one dose of study medication. Among the 266 Full Analysis Set (FAS) participants, 251 participants (123 participants in the LCZ696 + amlodipine group and 128 participants in the amlodipine group) had eligible ABPM at both baseline and endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.93", "spread": "0.56"}, {"groupId": "OG001", "value": "-0.82", "spread": "0.56"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean 24-hour ABPM Diastolic Blood Pressure (maDBP)", "description": "The change in mean 24 hour maDBP from baseline to end of the study was measured. A reduction from baseline indicates a positive treatment effect.", "populationDescription": "FAS: This set included all randomized participants who received at least one dose of study medication. Among the 266 Full Analysis Set (FAS) participants, 251 participants (123 participants in the LCZ696 + amlodipine group and 128 participants in the amlodipine group) had eligible ABPM at both baseline and endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.03", "spread": "0.38"}, {"groupId": "OG001", "value": "-0.33", "spread": "0.37"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The change in the patient's msSBP from baseline to end of the study was measured. A reduction from baseline indicates a positive treatment effect.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "136"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-19.60", "spread": "1.35"}, {"groupId": "OG001", "value": "-9.34", "spread": "1.33"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The change in the patient's msDBP from baseline to end of the study was measured. A reduction from baseline indicates a positive treatment effect.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "136"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.22", "spread": "0.83"}, {"groupId": "OG001", "value": "-3.96", "spread": "0.82"}]}]}]}, {"type": "SECONDARY", "title": "Change in Sitting Pulse Pressure (PP)", "description": "The change in the patient's mean sitting PP from baseline to end of the study was measured. Pulse pressure measures the difference in mean sitting systolic blood pressure and mean sitting diastolic blood pressure.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "136"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.31", "spread": "0.90"}, {"groupId": "OG001", "value": "-5.46", "spread": "0.89"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Systolic and Diastolic Blood Pressure Control (< 140/90 mmHg)", "description": "The number of participants achieving a systolic and diastolic blood pressure \\< 140/90 mmHg was measured. This outcome measure shows how well a given blood pressure treatment can achieve a given blood pressure target or goal. Participants who achieved the target blood pressure were determined based on the mean SBP and DBP measurements taken at the end of the study. If the participants' BP measurement was below the above target, they were considered to have successful blood pressure control.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "136"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "46"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Successful Response in msSBP (< 140 mmHg or a Reduction \u2265 20 mmHg From Baseline)", "description": "The number of participants who achieved successful treatment response in the msSBP of \\< 140mmHg or a reduction \u2265 20 mmHg from baseline after completing study treatment was measured. Participants who achieved either of the above targets were deemed as a having a successful response.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "136"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "53"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Successful Response in msDBP (< 90 mmHg or a Reduction \u2265 10 mmHg From Baseline)", "description": "The number of participants who achieved successful treatment response in msDBP of \\< 90mmHg or a reduction \u2265 10mmHg from baseline after completing study treatment was measured. Participants who achieved either of the above targets were deemed as having a successful response.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks of treatment", "groups": [{"id": "OG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "136"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "95"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Event", "description": "Participants were monitored for adverse events, serious adverse events and death.", "populationDescription": "Safety Set: The safety set included all randomized participants who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "136"}]}], "classes": [{"title": "Adverse Events (serious and non-serious)", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "29"}]}]}, {"title": "Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "eventGroups": [{"id": "EG000", "title": "LCZ696 and Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 130, "otherNumAffected": 13, "otherNumAtRisk": 130}, {"id": "EG001", "title": "Amlodipine", "description": "Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP \u2265145 mmHg and \\<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 136, "otherNumAffected": 19, "otherNumAtRisk": 136}], "otherEvents": [{"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 136}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 136}]}, {"term": "DYSLIPIDAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 136}]}, {"term": "HYPOKALAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 136}]}, {"term": "DIZZINESS", "organSystem": "Nervous system disorders", "sourceVocabulary": "16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 136}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "+1 (862) 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Pea", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}